JP2020508995A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020508995A5 JP2020508995A5 JP2019544887A JP2019544887A JP2020508995A5 JP 2020508995 A5 JP2020508995 A5 JP 2020508995A5 JP 2019544887 A JP2019544887 A JP 2019544887A JP 2019544887 A JP2019544887 A JP 2019544887A JP 2020508995 A5 JP2020508995 A5 JP 2020508995A5
- Authority
- JP
- Japan
- Prior art keywords
- smarca2
- activity
- smarca4
- function
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000702559 Homo sapiens Probable global transcription activator SNF2L2 Proteins 0.000 claims 37
- 102100031021 Probable global transcription activator SNF2L2 Human genes 0.000 claims 37
- 238000000034 method Methods 0.000 claims 28
- 239000005557 antagonist Substances 0.000 claims 27
- 230000000694 effects Effects 0.000 claims 27
- 206010028980 Neoplasm Diseases 0.000 claims 24
- 101000702545 Homo sapiens Transcription activator BRG1 Proteins 0.000 claims 22
- 102100031027 Transcription activator BRG1 Human genes 0.000 claims 22
- 201000011510 cancer Diseases 0.000 claims 20
- 238000004519 manufacturing process Methods 0.000 claims 3
- 229940126585 therapeutic drug Drugs 0.000 claims 3
- 108091006112 ATPases Proteins 0.000 claims 2
- 102000057290 Adenosine Triphosphatases Human genes 0.000 claims 2
- 108091033409 CRISPR Proteins 0.000 claims 2
- 108060004795 Methyltransferase Proteins 0.000 claims 2
- 101150054344 Smarca4 gene Proteins 0.000 claims 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 102000001805 Bromodomains Human genes 0.000 claims 1
- 108050009021 Bromodomains Proteins 0.000 claims 1
- 238000010354 CRISPR gene editing Methods 0.000 claims 1
- 206010064571 Gene mutation Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 101710163270 Nuclease Proteins 0.000 claims 1
- INAICWLVUAKEPB-QSTFCLMHSA-N PFI-3 Chemical group OC1=CC=CC=C1C(=O)\C=C\N1[C@@H](CN2C=3N=CC=CC=3)C[C@@H]2C1 INAICWLVUAKEPB-QSTFCLMHSA-N 0.000 claims 1
- 229940122059 SMARCA2 inhibitor Drugs 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 230000008995 epigenetic change Effects 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 230000004481 post-translational protein modification Effects 0.000 claims 1
- 230000004850 protein–protein interaction Effects 0.000 claims 1
- 239000002924 silencing RNA Substances 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022116375A JP2022136149A (ja) | 2017-02-28 | 2022-07-21 | 癌の処置のためのｓｍａｒｃａ２の阻害 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762464811P | 2017-02-28 | 2017-02-28 | |
| US62/464,811 | 2017-02-28 | ||
| US201762542241P | 2017-08-07 | 2017-08-07 | |
| US62/542,241 | 2017-08-07 | ||
| PCT/US2018/020124 WO2018160636A1 (en) | 2017-02-28 | 2018-02-28 | Inhibition of smarca2 for treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022116375A Division JP2022136149A (ja) | 2017-02-28 | 2022-07-21 | 癌の処置のためのｓｍａｒｃａ２の阻害 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020508995A JP2020508995A (ja) | 2020-03-26 |
| JP2020508995A5 true JP2020508995A5 (enExample) | 2021-04-08 |
Family
ID=63371135
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019544887A Pending JP2020508995A (ja) | 2017-02-28 | 2018-02-28 | 癌の処置のためのｓｍａｒｃａ２の阻害 |
| JP2022116375A Pending JP2022136149A (ja) | 2017-02-28 | 2022-07-21 | 癌の処置のためのｓｍａｒｃａ２の阻害 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022116375A Pending JP2022136149A (ja) | 2017-02-28 | 2022-07-21 | 癌の処置のためのｓｍａｒｃａ２の阻害 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20200069669A1 (enExample) |
| EP (1) | EP3589289A4 (enExample) |
| JP (2) | JP2020508995A (enExample) |
| KR (1) | KR20190140438A (enExample) |
| CN (1) | CN110366418A (enExample) |
| AU (2) | AU2018227774A1 (enExample) |
| BR (1) | BR112019017851A2 (enExample) |
| CA (1) | CA3054682A1 (enExample) |
| CL (1) | CL2019002427A1 (enExample) |
| IL (1) | IL268676A (enExample) |
| MX (2) | MX2019010149A (enExample) |
| SG (2) | SG11201907420VA (enExample) |
| WO (1) | WO2018160636A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017087885A1 (en) | 2015-11-19 | 2017-05-26 | Dana-Farber Cancer Institute, Inc. | Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers |
| AU2018227774A1 (en) * | 2017-02-28 | 2019-09-19 | Epizyme, Inc. | Inhibition of SMARCA2 for treatment of cancer |
| SG11202003664TA (en) | 2017-11-30 | 2020-05-28 | Arrakis Therapeutics Inc | Nucleic acid-binding photoprobes and uses thereof |
| CN112153984A (zh) | 2018-01-30 | 2020-12-29 | 福宏治疗公司 | 化合物及其用途 |
| WO2020081588A1 (en) | 2018-10-17 | 2020-04-23 | Dana-Farber Cancer Institute, Inc. | Swi/snf family chromatin remodeling complexes and uses thereof |
| JP2022508155A (ja) * | 2018-11-21 | 2022-01-19 | フォグホーン セラピューティクス インコーポレイテッド | がんを治療する方法 |
| US12509453B2 (en) | 2019-01-29 | 2025-12-30 | Foghorn Therapeutics Inc. | BRM/BRG1 inhibitors and uses thereof |
| US12384776B2 (en) | 2019-01-29 | 2025-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US12479852B2 (en) | 2019-06-27 | 2025-11-25 | Dana-Farber Cancer Institute, Inc. | Compounds, compositions, and methods for protein degradation |
| AU2020345178A1 (en) * | 2019-09-12 | 2022-03-03 | Aurigene Discovery Technologies Limited | Method for identifying responders to SMARCA2/4 degraders |
| TWI859406B (zh) | 2020-01-29 | 2024-10-21 | 美商福宏治療公司 | 化合物及其用途 |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| CN115867314A (zh) * | 2020-05-20 | 2023-03-28 | 福宏治疗公司 | 治疗癌症的方法 |
| JP2023536504A (ja) * | 2020-08-04 | 2023-08-25 | オーリジーン オンコロジー リミテッド | Ｓｍａｒｃａ２および／またはｓｍａｒｃａ４分解剤としての６置換ピリダジン化合物 |
| WO2024086577A1 (en) * | 2022-10-17 | 2024-04-25 | Foghorn Therapeutics Inc. | Methods of reducing or preventing metastases |
| CN116004644A (zh) * | 2023-01-19 | 2023-04-25 | 南京中澳转化医学研究院有限公司 | Smarca4突变体及其在结直肠癌药物开发中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2900301T3 (es) * | 2013-03-15 | 2022-03-16 | Novartis Ag | Biomarcadores asociados con la inhibición de BRM |
| WO2015005473A1 (ja) * | 2013-07-12 | 2015-01-15 | 独立行政法人国立がん研究センター | がんの治療への応答性を予測する方法 |
| US20160326596A1 (en) * | 2013-12-31 | 2016-11-10 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for the diagnosis and treatment of ovarian cancers that are associated with reduced smarca4 gene expression or protein function |
| MA41598A (fr) * | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| US20200129519A1 (en) * | 2016-06-08 | 2020-04-30 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| AU2018227774A1 (en) * | 2017-02-28 | 2019-09-19 | Epizyme, Inc. | Inhibition of SMARCA2 for treatment of cancer |
| EP3826999A1 (en) * | 2018-07-24 | 2021-06-02 | Epizyme Inc | Pyridin-2-one compounds useful as smarca2 antagonists |
-
2018
- 2018-02-28 AU AU2018227774A patent/AU2018227774A1/en not_active Abandoned
- 2018-02-28 SG SG11201907420VA patent/SG11201907420VA/en unknown
- 2018-02-28 WO PCT/US2018/020124 patent/WO2018160636A1/en not_active Ceased
- 2018-02-28 SG SG10202109335T patent/SG10202109335TA/en unknown
- 2018-02-28 MX MX2019010149A patent/MX2019010149A/es unknown
- 2018-02-28 CN CN201880014651.2A patent/CN110366418A/zh active Pending
- 2018-02-28 JP JP2019544887A patent/JP2020508995A/ja active Pending
- 2018-02-28 BR BR112019017851-1A patent/BR112019017851A2/pt not_active Application Discontinuation
- 2018-02-28 US US16/489,489 patent/US20200069669A1/en not_active Abandoned
- 2018-02-28 CA CA3054682A patent/CA3054682A1/en active Pending
- 2018-02-28 EP EP18760511.8A patent/EP3589289A4/en not_active Withdrawn
- 2018-02-28 KR KR1020197028241A patent/KR20190140438A/ko not_active Ceased
-
2019
- 2019-08-13 IL IL26867619A patent/IL268676A/en unknown
- 2019-08-23 CL CL2019002427A patent/CL2019002427A1/es unknown
- 2019-08-26 MX MX2024000253A patent/MX2024000253A/es unknown
-
2022
- 2022-06-24 US US17/848,885 patent/US20230000849A1/en active Pending
- 2022-07-21 JP JP2022116375A patent/JP2022136149A/ja active Pending
-
2024
- 2024-04-12 AU AU2024202398A patent/AU2024202398A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020508995A5 (enExample) | ||
| Dubbury et al. | CDK12 regulates DNA repair genes by suppressing intronic polyadenylation | |
| Miotto et al. | Selectivity of ORC binding sites and the relation to replication timing, fragile sites, and deletions in cancers | |
| Chicas et al. | Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence | |
| Walton et al. | PBRM1, SETD2 and BAP1—the trinity of 3p in clear cell renal cell carcinoma | |
| Valente et al. | p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa | |
| Taniue et al. | Long noncoding RNA UPAT promotes colon tumorigenesis by inhibiting degradation of UHRF1 | |
| Park et al. | Aicardi-Goutières syndrome-associated gene SAMHD1 preserves genome integrity by preventing R-loop formation at transcription–replication conflict regions | |
| Kondo et al. | Overexpression of the DNA sensor proteins, absent in melanoma 2 and interferon‐inducible 16, contributes to tumorigenesis of oral squamous cell carcinoma with p53 inactivation | |
| Tu et al. | Oncogenic RAS regulates BRIP1 expression to induce dissociation of BRCA1 from chromatin, inhibit DNA repair, and promote senescence | |
| Mohd-Sarip et al. | DOC1-dependent recruitment of NURD reveals antagonism with SWI/SNF during epithelial-mesenchymal transition in oral cancer cells | |
| Rashi-Elkeles et al. | Parallel profiling of the transcriptome, cistrome, and epigenome in the cellular response to ionizing radiation | |
| Llabata et al. | Multi-omics analysis identifies MGA as a negative regulator of the MYC pathway in lung adenocarcinoma | |
| North et al. | Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor | |
| Shu et al. | The epigenetic modifier PBRM1 restricts the basal activity of the innate immune system by repressing retinoic acid‐inducible gene‐I‐like receptor signalling and is a potential prognostic biomarker for colon cancer | |
| Chu et al. | Genotranscriptomic meta‐analysis of the CHD family chromatin remodelers in human cancers–initial evidence of an oncogenic role for CHD 7 | |
| Alexandrova et al. | An overview of candidate therapeutic target genes in ovarian cancer | |
| de Nonneville et al. | TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT | |
| Chen et al. | Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1 | |
| Xie et al. | Methotrexate induces DNA damage and inhibits homologous recombination repair in choriocarcinoma cells | |
| US20190136321A1 (en) | Use of translational profiling to identify target molecules for therapeutic treatment | |
| Janus et al. | Pro-inflammatory cytokine and high doses of ionizing radiation have similar effects on the expression of NF-kappaB-dependent genes | |
| Kumar et al. | HAT3-mediated acetylation of PCNA precedes PCNA monoubiquitination following exposure to UV radiation in Leishmania donovani | |
| Schmidt et al. | Screening analysis of ubiquitin ligases reveals G2E3 as a potential target for chemosensitizing cancer cells | |
| Bretz et al. | ΔNp63 activates the Fanconi anemia DNA repair pathway and limits the efficacy of cisplatin treatment in squamous cell carcinoma |